We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase...
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at...
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.17 | -6.14556782781 | 35.31 | 36.1974 | 31.5 | 529741 | 34.0922909 | CS |
4 | -0.66 | -1.95266272189 | 33.8 | 37.38 | 31.24 | 678210 | 33.50962414 | CS |
12 | -15.55 | -31.9367426576 | 48.69 | 49.76 | 30.91 | 699068 | 36.98821635 | CS |
26 | 8.88 | 36.6034624897 | 24.26 | 53.08 | 21.67 | 801428 | 38.61187021 | CS |
52 | 11.3 | 51.7399267399 | 21.84 | 53.08 | 13.57 | 632582 | 32.60290349 | CS |
156 | -39.66 | -54.478021978 | 72.8 | 108.465 | 13.57 | 512726 | 46.57017882 | CS |
260 | 11.7 | 54.5708955224 | 21.44 | 108.465 | 13.57 | 500186 | 46.71056042 | CS |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.05 (132.82%) | 310.28M |
GWAVGreenwave Technology Solutions Inc | $ 0.0387 (-7.86%) | 305.13M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.584899 (3.47%) | 223.84M |
SQQQProShares UltraPro Short QQQ | $ 10.02 (0.00%) | 161.89M |
CRKNCrown Electrokinetics Corporation | $ 0.0998 (-12.07%) | 155.13M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions